Cargando…

Hematologic and Cytogenetic Findings in Myelodysplastic Syndromes Treated with Recombinant Human Granulocyte Colony‐stimulating Factor

We administered recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) to four patients with myelodysplastic syndrome (MDS) and three patients with non‐MDS (two malignant lymphoma and one lung cancer) as a part of a phase II trial and analyzed the effects of rhG‐CSF on the neoplastic cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohyashiki, Kazuma, Ohyashiki, Junko H., Toyama, Keisuke, Takaku, Fumimaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 1989
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917852/
https://www.ncbi.nlm.nih.gov/pubmed/2480943
http://dx.doi.org/10.1111/j.1349-7006.1989.tb01725.x
_version_ 1783317303268474880
author Ohyashiki, Kazuma
Ohyashiki, Junko H.
Toyama, Keisuke
Takaku, Fumimaro
author_facet Ohyashiki, Kazuma
Ohyashiki, Junko H.
Toyama, Keisuke
Takaku, Fumimaro
author_sort Ohyashiki, Kazuma
collection PubMed
description We administered recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) to four patients with myelodysplastic syndrome (MDS) and three patients with non‐MDS (two malignant lymphoma and one lung cancer) as a part of a phase II trial and analyzed the effects of rhG‐CSF on the neoplastic cells of MDS by performing sequential chromosome analyses on the bone marrow cells. A greater than 3‐fold increase in neutrophil count was observed in the MDS patients after rhG‐CSF infusions, whereas the number of blasts in the bone marrow did not increase and none of them progressed into the leukemic phase. After rhG‐CSF treatment, the bone marrow cells obtained from patients without MDS did not show any particular chromosome abnormalities such as chromosomal breakage. On the contrary, two of the four MDS patients with acquired chromosome abnormalities showed a change in the frequency of marrow cells with clonal abnormalities after rhG‐CSF treatment; the proportion of metaphase cells with additional numerical chromosome abnormalities decreased in these two MDS patients. After discontinuation of the treatment, the constitution of marrow cells with chromosome changes reverted to that before treatment. The remaining two MDS patients did not show any particular chromosome changes after the rhG‐CSF treatment, indicating that rhG‐CSF may not promote the characteristics of dyshematopoiesis in MDS, and act on cells derived from an MDS clone .
format Online
Article
Text
id pubmed-5917852
institution National Center for Biotechnology Information
language English
publishDate 1989
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-59178522018-05-11 Hematologic and Cytogenetic Findings in Myelodysplastic Syndromes Treated with Recombinant Human Granulocyte Colony‐stimulating Factor Ohyashiki, Kazuma Ohyashiki, Junko H. Toyama, Keisuke Takaku, Fumimaro Jpn J Cancer Res Article We administered recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) to four patients with myelodysplastic syndrome (MDS) and three patients with non‐MDS (two malignant lymphoma and one lung cancer) as a part of a phase II trial and analyzed the effects of rhG‐CSF on the neoplastic cells of MDS by performing sequential chromosome analyses on the bone marrow cells. A greater than 3‐fold increase in neutrophil count was observed in the MDS patients after rhG‐CSF infusions, whereas the number of blasts in the bone marrow did not increase and none of them progressed into the leukemic phase. After rhG‐CSF treatment, the bone marrow cells obtained from patients without MDS did not show any particular chromosome abnormalities such as chromosomal breakage. On the contrary, two of the four MDS patients with acquired chromosome abnormalities showed a change in the frequency of marrow cells with clonal abnormalities after rhG‐CSF treatment; the proportion of metaphase cells with additional numerical chromosome abnormalities decreased in these two MDS patients. After discontinuation of the treatment, the constitution of marrow cells with chromosome changes reverted to that before treatment. The remaining two MDS patients did not show any particular chromosome changes after the rhG‐CSF treatment, indicating that rhG‐CSF may not promote the characteristics of dyshematopoiesis in MDS, and act on cells derived from an MDS clone . Blackwell Publishing Ltd 1989-09 /pmc/articles/PMC5917852/ /pubmed/2480943 http://dx.doi.org/10.1111/j.1349-7006.1989.tb01725.x Text en
spellingShingle Article
Ohyashiki, Kazuma
Ohyashiki, Junko H.
Toyama, Keisuke
Takaku, Fumimaro
Hematologic and Cytogenetic Findings in Myelodysplastic Syndromes Treated with Recombinant Human Granulocyte Colony‐stimulating Factor
title Hematologic and Cytogenetic Findings in Myelodysplastic Syndromes Treated with Recombinant Human Granulocyte Colony‐stimulating Factor
title_full Hematologic and Cytogenetic Findings in Myelodysplastic Syndromes Treated with Recombinant Human Granulocyte Colony‐stimulating Factor
title_fullStr Hematologic and Cytogenetic Findings in Myelodysplastic Syndromes Treated with Recombinant Human Granulocyte Colony‐stimulating Factor
title_full_unstemmed Hematologic and Cytogenetic Findings in Myelodysplastic Syndromes Treated with Recombinant Human Granulocyte Colony‐stimulating Factor
title_short Hematologic and Cytogenetic Findings in Myelodysplastic Syndromes Treated with Recombinant Human Granulocyte Colony‐stimulating Factor
title_sort hematologic and cytogenetic findings in myelodysplastic syndromes treated with recombinant human granulocyte colony‐stimulating factor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917852/
https://www.ncbi.nlm.nih.gov/pubmed/2480943
http://dx.doi.org/10.1111/j.1349-7006.1989.tb01725.x
work_keys_str_mv AT ohyashikikazuma hematologicandcytogeneticfindingsinmyelodysplasticsyndromestreatedwithrecombinanthumangranulocytecolonystimulatingfactor
AT ohyashikijunkoh hematologicandcytogeneticfindingsinmyelodysplasticsyndromestreatedwithrecombinanthumangranulocytecolonystimulatingfactor
AT toyamakeisuke hematologicandcytogeneticfindingsinmyelodysplasticsyndromestreatedwithrecombinanthumangranulocytecolonystimulatingfactor
AT takakufumimaro hematologicandcytogeneticfindingsinmyelodysplasticsyndromestreatedwithrecombinanthumangranulocytecolonystimulatingfactor